Abstract:Hepatitis B is a viral hepatitis, which is caused by infection of hepatitis B virus (HBV). This disease progresses to chronic hepatitis, cirrhosis and liver cancer. To treat hepatitis B, exclusion of virus and covalently closed circular DNA (cccDNA) that is formed in hepatocyte nucleus is necessary. A hepatitis B capsid protein (HBc) is an indispensable protein, which forms the capsid that encapsulates viral DNA. Since HBc is correlated to the transcriptional regulation of cccDNA, this protein would be an attractive target for complete cure of hepatitis B. By in silico screening of a library of compounds, a small compound, Cpd4 (1), which binds to a hydrophobic cavity located in the inner pocket on the tetramer interface of HBc proteins, was identified. In anti-HBV assays, this synthetic compound, Cpd4 (1) decreased the amount of HBV core related antigen (HBcrAg), which has been correlated with the proliferation of HBV, and decreased the amount of HBV surface antigen (HBsAg), which is correlated with the amount of cccDNA. Based on Cpd4 (1) as a lead compound, 20 derivatives of 1 were designed and synthesized and their structure-activity relationships were examined. As a result, specific interactions between each compound and amino acid residues of the target protein appeared to be unimportant but the shape/size of compounds which can bind to the hydrophobic cavity might be important in the expression of high anti-HBV activity, and a more potent derivative, TKB-HBV-CA-001 (3b), was discovered. These results will be useful in the development of novel anti-HBV agents for a complete cure of hepatitis B.

Design, Synthesis, And Bioactive Screen In Vitro Of Cyclohexyl (E)-4-(Hydroxyimino)-4-Phenylbutanoates And Their Ethers For Anti-Hepatitis B Virus Agents

Discovery of 5-Alkyl-2-pyrazol-oxazolidin-4-one Derivatives As Novel Hepatitis B Virus Capsid Assembly Modulators

Design, Synthesis and Bioactive Evaluation of Oxime Derivatives of Dehydrocholic Acid as Anti-Hepatitis B Virus Agents

Design, synthesis, and biological evaluation of novel (E)-1-arylethan-1-one O-((3-arylisoxazol-5-yl) methyl) oxime derivatives as potent non-nucleoside HBV inhibitors

Design and Synthesis of Novel Benzimidazole Derivatives As Inhibitors of Hepatitis B Virus

Synthesis and Anti‐HBV Activities Evaluation of New Ethyl 8‐imidazolylmethyl‐7‐hydroxyquinoline‐3‐carboxylate Derivatives in Vitro

Synthesis and anti-hepatitis B virus activity of a novel class of thiazolylbenzimidazole derivatives.

Design, synthesis and biological evaluation of novel dihydrobenzodioxine derivatives as HBV capsid protein inhibitors

Optimization and Synthesis of Pyridazinone Derivatives As Novel Inhibitors of Hepatitis B Virus by Inducing Genome-free Capsid Formation

Synthesis and Anti-Hepatitis B Virus Activity of Novel Benzimidazole Derivatives

Identification of 1-isopropylsulfonyl-2-amine benzimidazoles as a new class of inhibitors of hepatitis B virus.

Design, synthesis and anti-HBV activity study of novel HBV capsid assembly modulators

Design, synthesis and evaluation of heteroaryldihydropyrimidine analogues bearing spiro ring as hepatitis B virus capsid protein inhibitors

Design and synthesis of aminothiazole based Hepatitis B Virus (HBV) capsid inhibitors

Synthesis and In‐Vitro Anti‐Hepatitis‐B Virus Activity of 6h‐[1]benzothiopyrano[4,3‐b] Quinolin‐10‐ols

Synthesis and in Vitro Anti-Hepatitis B Virus Activity of 6H-[1]Benzothiopyrano[4,3-b]quinolin-9-ols.

Synthesis and Anti-HBV Activity of Novel Dihydropyrimidine Analogs

Design, Synthesis, Molecular Modeling Studies and Biological Evaluation of N'-Arylidene-6-(benzyloxy)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide Derivatives as Novel Anti-HCV Agents

4-Oxooctahydroquinoline-1(2H)-carboxamides as hepatitis B virus (HBV) capsid core protein assembly modulators

Development of anti-HBV agents targeting HBV capsid proteins

Recent advance of the hepatitis B virus inhibitors: a medicinal chemistry overview